$ALL

Four PEG-Driven GARP Winners for the Uncertainty of November 2025

Four PEG-driven GARP picks emerge as compelling options amid market turmoil, with ALL, SANM, PAHC and ENS highlighted for their strong growth metrics.

Original reporting
Zacks Commentary · Urmimala Biswas
Published Nov 20, 2025, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 21, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Four PEG-Driven GARP Winners for the Uncertainty of November 2025 — source image
Decision brief

The 30-second read

$ALLNeutralMed
01

Why it matters

If these stocks perform as expected, they could provide relative stability and growth in a volatile environment, but risks remain due to macroeconomic factors.

02

Market read

The stocks are relevant within their respective sectors, with potential to influence sector performance if gains materialize.

03

What to watch

Potential macroeconomic headwinds, sector-specific risks, and technical resistance levels not discussed in the article could impact stock performance.

Timing: Moderate; the article discusses near-term opportunities within the next few months.

Background

The article highlights PEG-driven GARP stocks as resilient options amid market turmoil, emphasizing growth metrics and valuation.

Company-level read

Ticker impact

$ALLNeutralMedium confidence
Context

Moderate relevance due to strong growth metrics highlighted in the article.

Expected impact

Potential modest upward movement over the medium term, contingent on broader market conditions.

Evidence & confidence

The article emphasizes growth metrics but lacks detailed technical analysis or current price data, leading to moderate confidence.

$SANMBullishHigh confidence
Context

High relevance as a PEG-driven GARP winner with favorable growth metrics.

Expected impact

Possible moderate appreciation in stock price, especially for swing traders.

Evidence & confidence

Strong growth metrics and positive sentiment support a favorable outlook, though technical confirmation is recommended.

$PAHCBullishHigh confidence
Context

High relevance with notable growth metrics highlighted.

Expected impact

Expected moderate upward trend, suitable for swing traders.

Evidence & confidence

The article's emphasis on growth metrics and favorable sentiment suggest a positive trajectory, but current technical levels should be verified.

$ENSBullishHigh confidence
Context

High relevance based on the article's focus on growth metrics.

Expected impact

Potential for short to medium-term gains, especially for swing traders.

Evidence & confidence

Strong growth metrics and positive sentiment support a bullish outlook, pending technical confirmation.

Market effects

The highlighted stocks span Life Sciences, Retail & Wholesale, Financial Markets, and Manufacturing sectors, indicating a broad market impact if these stocks perform well.

Primarily U.S.-based stocks; potential influence on regional indices if significant gains occur.

Limited; the stocks are primarily regional, but positive performance could influence global sentiment in respective sectors.

Counterpoint

While growth metrics are promising, broader market uncertainties and potential overvaluation could limit gains. Some stocks may experience corrections despite positive fundamentals.

Key entities

  • Allscripts Healthcare Solutions

    A healthcare IT solutions provider.

  • Sanmina Corporation

    A global electronics manufacturing services company.

  • Pharmerica Corporation

    A provider of pharmacy services.

  • Enersys

    A global leader in stored energy solutions.

  • Bionano Genomics

    A life sciences instrumentation company.

Related articles

$ALLMed

Why is Allstate stock sliding today?

Allstate shares fell about 1% in pre-open trading to around $272.26 after Wells Fargo downgraded the insurer from Equal Weight to Underweight and cut its price target to $250. The downgrade followed Allstate’s Aug. 6 Q2 2026 results, where adjusted EPS was $8.99, net income rose 55.9% to $3.2B, and the combined ratio improved to 86.6.

$ALLMedAI 8/10

Allstate Q2 Net Income Jumps 56% on Underwriting

Allstate Corp. reported Q2 2026 net income applicable to common shareholders of about $3.2 billion, up nearly 56% from about $2.1 billion a year earlier, as underwriting income rose 56.7% to about $2.0 billion. The Property-Liability combined ratio was 86.6. Northbrook, Illinois-based insurer said H1 2026 net income more than doubled to about $5.7 billion.

$ALLMed

Allstate (NYSE:ALL) Reports Bullish Q2 CY2026

Allstate (NYSE:ALL) reported Q2 CY2026 results. According to the company, revenue rose 10.8% year on year to $18.6 billion and exceeded Wall Street estimates by 7.8%. Non-GAAP profit was $8.99 per share, 48% above consensus. The stock was flat at $266.00 after the release.

$ALLMedAI 8/10

Allstate Reports Excellent Operating Results

Allstate (NYSE: ALL) reported Q2 2026 results. Revenues rose to $18.6 billion (+11.8% YoY) on higher policies in force, higher homeowners premiums, and investment results. Net income was $3.2 billion, adjusted net income $2.3 billion ($8.99 per diluted share). Share repurchases increased to $1.0 billion. Property-Liability combined ratio improved to 86.6.

$ALLMedAI 8/10

ALLSTATE CORP (ALL): Results of Operations and Financial Condition

ALLSTATE CORP (ALL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 allcorp63026earningsreleas.htm EX-99.1 Document Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Nick Nottoli Allister Gobin Media Relations Investor Relations mediateam@allstate.com invrel@allstate.com Allstate Reports Excellent Operating Results NORTHBROOK, Ill., August 5

$SANMMed

5 Insightful Analyst Questions From Sanmina’s Q2 Earnings Call

Sanmina reported Q2 revenue of $3.46B, up 69.7% year over year and slightly above estimates, and adjusted EPS of $3.31, above forecasts. Management cited demand in communications networks, cloud and AI infrastructure, plus non-recurring engineering services. Q3 guidance midpoint calls for $3.45B revenue and $3.20 adjusted EPS. Analysts asked about margin sustainability, customer wins, and ZT Systems.